Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |2 December 2003

Consequences of Serious Bleeding Complications from Warfarin Free

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • The summary below is from the full report titled Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism. A Meta-Analysis. It is in the 2 December 2003 issue of Annals of Internal Medicine (volume 139, pages 893-900). The authors are L.A. Linkins, P.T. Choi, and J.D. Douketis.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link

What is the problem and what is known about it so far?

Blood clots in the deep veins of the legs or pelvis are called deep venous thrombosis (DVT). These blood clots are dangerous because they can break free and travel to the lungs. This problem, called pulmonary embolism (clot in the lung), can be fatal. Doctors typically treat patients with DVT with blood-thinning drugs for 3 to 6 months. Some patients with high risks for repeated clots need even longer treatment. The blood-thinning drugs prevent the formation of new clots, reduce the risk that a clot will travel to the lungs, and prevent repeated clots. Doctors often use a powerful blood-thinning drug called warfarin to prevent repeated clots in patients with DVT. People taking this drug need frequent blood tests to make sure that the dose being given reduces the blood's tendency to clot, but not so much that bleeding occurs spontaneously. Even with careful monitoring, some patients who take warfarin have bleeding complications. The consequences of the bleeding complications aren't well known.

Why did the researchers do this particular study?

To describe the frequency and consequences of major bleeding in patients taking warfarin for DVT.

Who was studied?

10,757 patients from 33 studies.

How was the study done?

Rather than doing a new study, the researchers looked at previous studies that involved patients with DVT who were treated with warfarin-type drugs for at least 3 months. Patients in these studies weren't allowed to take other drugs, such as aspirin, that might affect blood clotting. Their doses of warfarin and clotting ability were monitored with particular blood tests (international normalized ratio targets of 2.0 to 3.0). The researchers summarized numbers of patients with major bleeding events that required hospitalization or a blood transfusion, numbers of patients with bleeding inside the skull (intracranial bleeding), and numbers of patients who died.

What did the researchers find?

Patients in the studies had 276 major bleeding events; 37 of these were fatal. Of 24 intracranial bleeding episodes, 11 were fatal. Risks for bleeding appeared highest within the first 3 months of starting warfarin. The summary estimated number of major bleeding events per 1000 patients taking warfarin for 1 year was 72. The summary estimated number of deaths from bleeding per 1000 patients taking warfarin for 1 year was 13.

What were the limitations of the study?

The reviewed studies used slightly different definitions of major bleeding events. Exact estimates of when bleeding occurred (for example, within 10 days of starting warfarin therapy) weren't possible because many studies did not report the time of each bleeding event.

What are the implications of the study?

Major bleeding events have serious consequences in people taking warfarin for DVT. About 1 in 8 people with major bleeding episodes die. Nearly 10% of major bleeding episodes are intracranial, and nearly 50% of these are fatal.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Consequences of Serious Bleeding Complications from Warfarin. Ann Intern Med. 2003;139:I–22. doi: 10.7326/0003-4819-139-11-200312020-00002

Download citation file:

  • RIS (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2018

×
Permissions

Published: Ann Intern Med. 2003;139(11):I-22.

DOI: 10.7326/0003-4819-139-11-200312020-00002

©
2003 American College of Physicians
0 Citations

See Also

Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis
View MoreView Less

Related Articles

Update in Hematology and Oncology: Evidence Published in 2016
Annals of Internal Medicine; 166 (7): W27-W32
Update in General Internal Medicine: Evidence Published in 2016
Annals of Internal Medicine; 166 (7): W11-W15
After PCI with stents for AF, adding rivaroxaban vs warfarin to antiplatelet drugs reduced bleeding
Annals of Internal Medicine; 166 (6): JC29
After treating unprovoked PE with VKAs for 6 months, warfarin for 18 more months reduced a composite of VTE or major bleeding
Annals of Internal Medicine; 163 (10): JC6
View MoreView Less

Journal Club

After PCI with stents for AF, adding rivaroxaban vs warfarin to antiplatelet drugs reduced bleeding
Annals of Internal Medicine; 166 (6): JC29
After treating unprovoked PE with VKAs for 6 months, warfarin for 18 more months reduced a composite of VTE or major bleeding
Annals of Internal Medicine; 163 (10): JC6
In atrial fibrillation, dabigatran had similar efficacy to warfarin but caused less bleeding in higher GFR
Annals of Internal Medicine; 161 (4): JC7
Edoxaban was noninferior to warfarin for preventing recurrent venous thromboembolism, with less bleeding
Annals of Internal Medicine; 160 (2): JC4
View MoreView Less

Related Point of Care

Acute Gastrointestinal Bleeding
Annals of Internal Medicine; 159 (3): ITC2-1
View MoreView Less

Related Topics

Venous Thromboembolism

Venous Thromboembolism.

PubMed Articles

Postpartum blood transfusion and hemorrhage as independent risk factors for venous thromboembolism.
Thromb Res 2018;
The effect of postoperative steroids on post-tonsillectomy pain and need for postoperative physician contact.
Laryngoscope 2018.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Online First RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards

  • Personae Photography Prize
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2018 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×